Today MacroGenics (MGNX) announced that it had closed on its previously announced (October 25) Â license agreement with Incyte (INCY). For an upfront payment of $150 million and up to $420 million in milestone payments Incyte gained the exclusive global rights to develop and commercialize MGA012, an anti-PD-1 monoclonal antibody. (PD-1, also know as programmed cell […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
